中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.019 seconds)

    OmpA and Asp14 in vaccine compositions and as diagnostic targets
    1.
    发明授权
    OmpA and Asp14 in vaccine compositions and as diagnostic targets 有权

    公开(公告)号：US10736951B2

    公开(公告)日：2020-08-11

    申请号：US16454797

    申请日：2019-06-27

    Applicant: Virginia Commonwealth University

    Inventor： Jason A. Carlyon

    IPC: A61K39/02 ,  A61K39/40 ,  C07K16/12 ,  G01N33/569 ,  A61K39/00

    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

    OmpA and Asp14 in vaccine compositions and as diagnostic targets
    5.
    发明授权
    OmpA and Asp14 in vaccine compositions and as diagnostic targets 有权

    公开(公告)号：US10039815B2

    公开(公告)日：2018-08-07

    申请号：US15477137

    申请日：2017-04-03

    Applicant: Virginia Commonwealth University

    Inventor： Jason A. Carlyon

    IPC: A61K39/02 ,  A61K39/00

    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

    Chimeric vaccine antigens for anaplasmosis
    6.
    发明授权
    Chimeric vaccine antigens for anaplasmosis 有权

    公开(公告)号：US12239696B2

    公开(公告)日：2025-03-04

    申请号：US17590290

    申请日：2022-02-01

    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

    Inventor： Richard T. Marconi ,  Jason A. Carlyon

    IPC: A61K39/02 ,  A61P31/04 ,  A61P37/04 ,  C07K14/195

    Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.

    Chimeric vaccine antigens for anaplasmosis
    7.
    发明授权
    Chimeric vaccine antigens for anaplasmosis 有权

    公开(公告)号：US11273213B2

    公开(公告)日：2022-03-15

    申请号：US17048296

    申请日：2019-04-17

    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

    Inventor： Richard T. Marconi ,  Jason A. Carlyon

    IPC: A61K39/02 ,  A61P37/04 ,  A61P31/04 ,  C07K14/195

    Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.

    OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS
    10.
    发明申请
    OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS 审中-公开

    公开(公告)号：US20190336592A1

    公开(公告)日：2019-11-07

    申请号：US16454797

    申请日：2019-06-27

    Applicant: Virginia Commonwealth University

    Inventor： Jason A. Carlyon

    IPC: A61K39/02 ,  G01N33/569 ,  A61K39/40 ,  C07K16/12

    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

Patent Agency Ranking